Vaccine (Peptide vaccine) · Immune activation, directed at glioblastoma tumor-associated peptides (patient-selected tumor-associated antige · developed by Immatics Biotechnologies GmbH
Synthetic Glioblastoma Tumor-associated Peptides Vaccine is a personalized peptide-based cancer vaccine of five to ten peptides selected according to the patient's tumor-associated antigen expression. It stimulates a cytotoxic T-lymphocyte response against tumor cells expressing these peptides, and is studied in glioblastoma.
Summary written with AI from the sources listed at the end of this page.
| Trial | Phase | Condition | Status | Sponsor |
|---|---|---|---|---|
| NCT02149225 | Phase 1 | Glioblastoma | Completed | IMTX |
Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.
Glioblastoma
See IMTX's upcoming FDA decisions, trial readouts, cash runway and dilution risk, updated every day from SEC, FDA and ClinicalTrials.gov filings.
IMTX catalysts and pipeline →